Dapagliflozin vs empagliflozin in patients with chronic heart failure: a registry analysis
CHF patients prescribed with dapagliflozin had poorer outcomes than their empagliflozin-prescribed peers over the initial 6 months of treatment. Data emphasize a need for a direct randomized comparison of the two treatments in this setting.
Authors
- Vladimir Trkulja (ORCID: https://orcid.org/0000-0002-0968-1194)
- Ivana Jurin (ORCID: https://orcid.org/0000-0002-2637-9691)
- Irzal Hadžibegović (ORCID: https://orcid.org/0000-0002-3768-9134)
- Hrvoje Jurin (ORCID: https://orcid.org/0000-0002-2599-553X)
- Diana Rudan (ORCID: https://orcid.org/0000-0001-9473-2517)
- Šime Manola (ORCID: https://orcid.org/0000-0001-6444-2674)
- Marija Radić (ORCID: https://orcid.org/0000-0003-2317-6300)
- Nikola Pavlović (ORCID: https://orcid.org/0000-0003-3452-389X)
Institutions
- University Hospital Centre Zagreb (HR)
- University of Zagreb (HR)
- University Hospital Dubrava (HR)
- University North (HR)
- University of Osijek (HR)
Publication Details
- Journal
- Croatian Medical Journal
- Published
- 2025-04-01
- DOI
- https://doi.org/10.3325/cmj.2025.66.135
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00